Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0001156039
$445.28
+2.57% · delayed ~15 min
Last price from Oct 22, 2026
$98.28B market value
From Elevance Health, Inc.'s FY2025 10-K, filed Feb 6, 2026 · read the filing
Elevance Health sells insurance. It took in $199.13B last year, which makes it a very large company. Of every dollar it sells, about 3 cents is left as profit.
The financial picture is mixed, with profitability, growth and debt needing attention.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From Elevance Health, Inc.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Free cash flow
$4.55B → $3.17B
Revenue
$177.01B → $199.13B
Gross profit
$157.26B → $177.95B
Operating income
$7.86B → $7.20B
Measured against FY2024, from the 10-K filed Feb 6, 2026
Deteriorated: -30.3%
$4.55B to $3.17BSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
How the latest move compares (quote delayed ~15 min), and what was published around it
ELV rose 2.57% on the latest quote. The average Financials company tracked here moved +1.09%, and the S&P 500 −1.04%. That is 1.5 points above its sector and 3.6 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 28 analysts covering this company, as of . Their views, not this site's.
Of 28 analysts publishing on this company, 7 say strong buy, 12 say buy and 9 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 3 cents of every dollar of sales as profit, earning $5.66B last year.
Slowly. Sales grew 12.5% last year.
For every $1 it owes, it owns $1.57 in assets. Banks and insurers always carry high debt — that is how lending works — so this is normal for the industry and not comparable with other sectors.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 27 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 36% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $5.66B and generated $4.29B of cash from operations.
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 6, 2026Filing for FY2025 | FY202410-K · Feb 20, 2025Filing for FY2024 | FY202310-K · Feb 21, 2024Filing for FY2023 | FY202210-K · Feb 21, 2024Filing for FY2022 | FY202110-K · Feb 21, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $199.13B | $177.01B | $171.34B | $156.59B | $138.64B | +12.5% |
| Cost of revenue | $21.18B | $19.75B | $17.29B | $13.04B | $10.89B | +7.2% |
| Gross profit | $177.95B† | $157.26B† | $154.05B† | $143.56B† | $127.74B† | +13.2% |
| Gross marginGross profit ÷ revenueWhat is this? | 89.4% | 88.8% | 89.9% | 91.7% | 92.1% | +0.5 pts |
| Selling, general and administrative | $20.98B | $20.02B | $20.09B | $17.70B | $15.92B | +4.8% |
| Operating income | $7.20B | $7.86B | $8.50B | $8.28B | $7.56B | −8.4% |
| Operating marginOperating income ÷ revenueWhat is this? | 3.6% | 4.4% | 5.0% | 5.3% | 5.5% | −0.8 pts |
| Interest expense | $1.40B | $1.19B | $1.03B | $851.0M | $798.0M | +18.3% |
| Income before tax | $6.71B | $7.90B | $7.71B | $7.60B | $8.00B | −15.1% |
| Net income | $5.66B | $5.98B | $5.99B | $5.89B | $6.16B | −5.3% |
| Net marginNet income ÷ revenueWhat is this? | 2.8% | 3.4% | 3.5% | 3.8% | 4.4% | −0.5 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $25.65 | $26.29 | $25.69 | $24.77 | $25.47 | −2.4% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| ELVElevance Health, Inc. · this page | 6.0/10 | 6/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Had shares withheld to cover taxes — 4,161 shares at $386.43 ($1.6M)
Holds 27,876 shares after this filing.
Was granted or awarded shares — 2,627 shares
Holds 30,503 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q3 FY2026
Earnings per share +17.9% · Cash +18.8% · Profit +14.8% — against Q3 FY2025
Read the filingPublished results
Read the filingWrite down why you are following Elevance Health, Inc., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 264 subsidiaries named in its 10-K, incorporated across 43 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from ELV's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 6, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 6.0 | 6/9 | 10-K, filed Feb 6, 2026 |
| FY2024 | 6.0 | 4/9 | 10-K, filed Feb 20, 2025 |
| FY2023 | 6.0 | 8/9 | 10-K, filed Feb 21, 2024 |
| FY2022 | 6.0 | 5/9 | 10-K, filed Feb 15, 2023 |
| FY2021 | 6.0 | 7/9 | 10-K, filed Feb 16, 2022 |
| FY2020 | 7.3 | 6/9 | 10-K, filed Feb 18, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
not reported — Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +12.5%
$177.01B to $199.13BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +13.2%
$157.26B to $177.95BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: -8.4%
$7.86B to $7.20BNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -5.3%
$5.98B to $5.66BNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: +5.4%
$29.22B to $30.80BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: +14.5%
$8.29B to $9.49BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -3.0%
227.5M to 220.7MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Changed: -11.1%
$1.26B to $1.12BNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Q3 FY2026 against Q3 FY2025, from the 10-Q filed Oct 21, 2026 — read it.
Improved: +17.9%
$5.35 to $6.32Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +18.8%
$8.71B to $10.35BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +14.8%
$1.19B to $1.36BNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: -2.7%
222.0M to 216.1MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q3 FY2026 against Q2 FY2026, from the 10-Q filed Oct 21, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: -28.0%
$1.76B to $1.27BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -6.7%
$1.46B to $1.36BNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −1.0 pts
3.5% to 2.5%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: -6.4%
$6.75 to $6.32Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
5 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.2% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 17.0x — investors pay $17.0 for each $1 of trailing profit.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Reported annual figures
| 12.5% |
| 2.8% |
| 17.36x |
| 1.77x |
| UNHUNITEDHEALTH GROUP INC | 6.0/10 | 7/9 | 11.8% | 2.7% | 31.94x | 2.08x |
|---|
| HUMHUMANA INC | 6.0/10 | 5/8 | 10.1% | 0.9% | 42.75x | 1.77x |
|---|
| CNCCENTENE CORP | 4.7/10 | 4/9 | 20.0% | -3.8% | — | 2.84x |
|---|
| MOHMOLINA HEALTHCARE, INC. | 6.0/10 | 4/9 | 11.7% | 1.0% | 23.41x | 2.83x |
|---|
| Median of peers | 6.0/10 | — | 11.8% | 1.0% | 31.94x | 2.45x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Had shares withheld to cover taxes — 144 shares at $405.84 ($58.4K)
Holds 6,530 shares after this filing.
Had shares withheld to cover taxes — 94 shares at $405.84 ($38.1K)
Holds 7,485 shares after this filing.
Had shares withheld to cover taxes — 255 shares at $414.78 ($105.8K)
Holds 7,230 shares after this filing.
Bought on the open market — 680 shares at $366.41 ($249.2K)
Holds 169,931 shares after this filing.
Bought on the open market — 2,045 shares at $368.25 ($753.1K)
Holds 171,976 shares after this filing.
Bought on the open market — 1,000 shares at $366.05 ($366.1K)
Holds 10,908 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 10,584 shares ($4.7M) on or after .
Shares originally obtained via Restricted Stock.
Filed notice to sell 1,500 shares ($629.9K) on or after .
Shares originally obtained via Stock Award.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Made a Regulation FD disclosure
Quarterly report for Q2 FY2026
Operating margin −1.4 pts · Operating income -27.3% · Profit -16.1% — against Q2 FY2025
Read the filingPublished results
Read the filingMade a Regulation FD disclosure
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Operating margin −2.3 pts · Free cash flow +399.0% · Operating income -34.2% — against Q1 FY2025
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingMade a Regulation FD disclosure
Read the filingReported another event
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingAnnual report for FY2025
Revenue +12.5% · Free cash flow -30.3% · Gross profit +13.2% — against FY2024
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Revenue +12.4% · Profit +17.0% · Earnings per share +22.2% — against Q3 FY2024
Read the filingPublished results
Read the filingReported another event
Read the filingThe first 40 of 264. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-06. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
ELV Q3 deep dive: Carelon expansion and Medicaid margin actions underpin raised outlook
Yahoo ·
Baird Maintains Neutral on Elevance Health, Raises Price Target to $406
Benzinga ·
Elevance: 3 Key Takeaways for Long-Term Investors
Yahoo ·
Elevance Health (ELV) Names Jeff Park Carelon President In Services Leadership Shift
Yahoo ·
2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRG
Yahoo ·
Elevance Health, Inc. (ELV) Hits Fresh High: Is There Still Room to Run?
Yahoo ·
Elevance (ELV) Q3 2026 Earnings Call Transcript
Yahoo ·
Elevance Health Inc. Q3 2026 Earnings Call Summary
Yahoo ·
What Elevance Health (ELV) Said on Its Q3 Earnings Call
Yahoo ·
Elevance Health Posts Earnings Beat, Lifts Guidance. CFO Sees a ‘Clear Path’ to Growth.
Yahoo ·
ELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlook
Yahoo ·
SpaceX earnings roundup, Meta earnings preview, and tech trade fears
Yahoo ·
Primary sources and further research